Bazedoxifene/conjugated estrogens: Phase III data

Data from a double-blind, placebo-controlled Phase III trial showed that bazedoxifene/conjugated estrogens (BZA/CE) missed the primary endpoint of significantly reducing the rate of endometrial hyperp...